Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05886816 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19

StatusCompleted
PhasePhase 2
Started2024-03-01
View on ClinicalTrials.gov ↗

Amendment history

2026-09-22
Trial completed
Primary completion confirmed: February 2026 (last estimated July 2026)
2026-03-12
Study Identification, Study Status, Oversight v5
Study titlerevised
Mitoquinone/mitoquinolMitoquinol Mesylate Asas Oral and Safe Postexposure Prophylaxis for Covid-19
2025-03-10
Study Identification, Study Status, Oversight v4
Primary completion date2025-07-31→2026-07-31
Completion date2025-07-31→2026-07-31
Study titlerevised
Mitoquinone/Mitoquinolmitoquinol Mesylate asAs Oral and Safe Postexposure Prophylaxis for Covid-19
2024-03-07
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-02-01→confirmed 2024-03-01
Study sites0→1
2023-11-29
Study Status v2
Start date2023-11-01→2024-02-01
2023-10-01
Study Status v1
Start date2023-09-01→2023-11-01
2023-06-01
Original filing
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after high-risk exposure to a person with confirmed SARS-CoV-2 infection.
Trial Details
NCT Number NCT05886816
Lead Sponsor University of Texas Southwestern Medical Center
Conditions SARS-CoV Infection, COVID-19
Enrollment 122 participants
Start Date 2024-03-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-21